Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Thyroid Neoplasms 6Thyroid Cancer, Papillary 2Adenocarcinoma, Follicular 2Thyroid Nodule 1Thyroid Diseases 1Neoplasm Metastasis 1Hyperthyroidism 1

Interventions

Magnetic Resonance Spectroscopy 5trametinib 3Specimen Handling 3dabrafenib 2cabozantinib 2X-Rays 2Iodine-131 2Interviews as Topic 2tremelimumab 1spartalizumab 1pembrolizumab 1omipalisib 1lenvatinib 1gallium Ga 68 dotatate 1durvalumab 1cobimetinib 1Vemurafenib 1Thyrotropin Alfa 1Sodium Iodide 1Phantoms, Imaging 1Nivolumab 1Ipilimumab 1Iodine-124 1High-Energy Shock Waves 1Glycoprotein Hormones, alpha Subunit 1Counseling 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma, Follicular × Iodine-131 × 1 year × Clear all
NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2 Recruiting
21 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡